Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Hypoglycaemia risk favours nateglinide-based therapy

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Hypoglycaemia risk favours nateglinide-based therapy. React. Wkly. 1080, 4 (2005). https://doi.org/10.2165/00128415-200510800-00010

    Download citation

    Keywords

    • Type Diabetes Mellitus
    • Metformin
    • Type Diabetes
    • Fasting Plasma Glucose
    • Glycaemic Control